Sanofi, Mylan Debate If EpiPen Competition Was A Price War Or A Monopoly
TOPEKA, Kan. — A motion to dismiss an EpiPen antitrust lawsuit continued to play out in two federal courts Sept. 14 when defendant Sanofi-Aventis U.S. LLC filed its opposition and defendant...To view the full article, register now.
Already a subscriber? Click here to view full article